Tertiary Lymphoid Structures Are Associated with Favorable Clinical Outcomes and Negatively Correlated with Cancer-Associated Fibroblasts in Esophageal Cancer
Tomoyoshi Kunitomo, Kazuhiro Noma, Noriyuki Nishiwaki, Seitaro Nishimura, Yasushige Takeda, Hijiri Matsumoto, Tatsuya Takahashi, Kento Kawasaki, Masaaki Akai, Naoaki Maeda, Satoru Kikuchi, Shunsuke Tanabe, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

TL;DR
Tertiary lymphoid structures in esophageal cancer are linked to better outcomes and are negatively related to cancer-associated fibroblasts.
Contribution
This study identifies TLSs as a prognostic factor and reveals their inverse relationship with CAFs in esophageal cancer.
Findings
TLS presence correlates with improved overall and progression-free survival in esophageal cancer patients.
TLSs are negatively correlated with cancer-associated fibroblasts in the tumor microenvironment.
TLSs are associated with increased plasma cell infiltration and better nutritional status.
Abstract
Tertiary lymphoid structures (TLSs) are immune cell aggregates that can develop within tumors. In esophageal cancer, we found that TLSs are present and associated with better patient outcomes. We also observed that cancer-associated fibroblasts (CAFs), which are important components of the tumor microenvironment, are related to TLS formation. These findings suggest that CAFs may influence the development of TLSs. Therapies targeting CAFs could therefore enhance TLS formation and potentially improve prognosis in patients with esophageal cancer. Background: Esophageal cancer remains a highly aggressive malignant tumor with poor prognosis, despite advances in combination therapies and novel immunotherapies. Tertiary lymphoid structures (TLSs), characterized by densely packed CD20+ B cells in a germinal-center-like structure, have recently been recognized as immune-stimulating components…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsEsophageal Cancer Research and Treatment · Lung Cancer Treatments and Mutations · Cancer Immunotherapy and Biomarkers
